Nektar Therapeutics (NKTR) Accumulated Expenses (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Accumulated Expenses of $5.0 million for Q1 2026, little changed year-over-year from $5.0 million in Q1 2025, and down 77.51% quarter-over-quarter from $22.3 million in Q4 2025.
Nektar Therapeutics (NKTR) Accumulated Expenses (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $5.0 million for Q1 2026.
- In Q1 2026, Accumulated Expenses changed 0.36% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $5.0 million (changed 0.36% YoY), while the FY2025 annual figure was $22.3 million, down 25.69% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $5.0 million, down from $22.3 million in the prior quarter.
- The five-year high for Accumulated Expenses was $37.4 million in Q1 2023, with the low at $5.0 million in Q1 2026.
- The 5-year median for Accumulated Expenses is $24.4 million (2022), against an average of $21.3 million.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses plunged 84.81% in 2023, then soared 439.74% in 2024.
- Nektar Therapeutics' Accumulated Expenses stood at $36.6 million in 2022, then slumped by 84.81% to $5.6 million in 2023, then jumped by 439.74% to $30.0 million in 2024, then retreated by 25.69% to $22.3 million in 2025, then tumbled by 77.51% to $5.0 million in 2026.
- Business Quant data shows NKTR's Accumulated Expenses at $5.0 million in Q1 2026, $22.3 million in Q4 2025, and $8.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.01 Mn |
| Dec 31, 2025 | 22.27 Mn |
| Sep 30, 2025 | 8.61 Mn |
| Jun 30, 2025 | 6.55 Mn |
| Mar 31, 2025 | 5.03 Mn |
| Dec 31, 2024 | 29.97 Mn |
| Sep 30, 2024 | 32.38 Mn |
| Jun 30, 2024 | 29.51 Mn |
| Mar 31, 2024 | 7.38 Mn |
| Dec 31, 2023 | 5.55 Mn |
| Sep 30, 2023 | 29.73 Mn |
| Jun 30, 2023 | 29.14 Mn |
| Mar 31, 2023 | 37.41 Mn |
| Dec 31, 2022 | 36.56 Mn |
| Sep 30, 2022 | 24.39 Mn |
| Jun 30, 2022 | 30.32 Mn |
| Mar 31, 2022 | 22.65 Mn |
| Dec 31, 2021 | 15.74 Mn |
| Sep 30, 2021 | 32.88 Mn |
| Jun 30, 2021 | 28.67 Mn |